However, a common occurrence in these studies was that the majority of patients undergoing intravitreal anti-VEGF injections were treated for diabetic retinopathy; hence, these changes could be attributed to the endothelial changes associated with diabetes itself, rather than to the direct effects of anti-VEGF on the corneal endothelium. The gene discussed is VEGFA; the disease is diabetes mellitus.